Marpai Q3 2025 Earnings Call - Strategic Pivot to Operational Efficiency and Sales Growth Amid Revenue Decline
Summary
Marpai's Q3 2025 earnings reveal a stark 42% drop in net revenues year-over-year to $4 million, juxtaposed with a commendable 24% reduction in operating expenses. The company, led by CEO Damien Lamendola and COO Dallas Script, underscores a disciplined turnaround strategy focused on operational efficiency, technological upgrades, and sales momentum. New leadership at the COO level has rapidly shifted emphasis towards client retention and new business acquisition, with high double-digit new client deals locked in for early 2026, driven in part by the relaunch of their Marpai Rx program. A recent $3.9 million PIPE funding round bolsters the balance sheet with the necessary capital to fuel final turnaround phases and platform enhancements. While financial losses persist, slight improvements in operating loss and per-share loss mark incremental progress. Marpai’s narrative centers on positioning itself as a scalable, tech-enabled disruptor in the vast U.S. healthcare market by offering smarter, cost-efficient solutions amid thriving demand for self-funded benefit plans and third-party administrator services.
Key Takeaways
- Net revenues fell 42% year-over-year to $4 million in Q3 2025, signaling continued top-line challenges.
- Operating expenses improved by 24%, reflecting disciplined cost control efforts during the turnaround.
- Operating loss slightly improved by 2% to $3.5 million, with net loss also improving marginally by 2% to $3 million.
- Basic and diluted loss per share narrowed by $0.10 to $0.20, indicating incremental financial progress.
- Marpai completed a $3.9 million PIPE financing with long-term family office investors, strengthening the capital base.
- The company is consolidating claims processing onto a new platform, expected to drive further cost savings.
- New COO Dallas Script, who joined in Q3, is driving a client-centric approach emphasizing retention and new business growth through clear KPIs.
- High double-digit new client deals are already secured for January 1, 2026, amid the peak sales cycle for health benefit plans.
- Marpai Rx, the company's pharmacy program, is highlighted as a significant differentiator and competitive advantage in winning new clients.
- CEO Damien Lamendola personally invested $1.7 million in Q3 and emphasizes a mission focused on smarter healthcare with better outcomes and scalable growth.
- The third-party administrator (TPA) industry is poised for rapid expansion, with a total addressable market forecasted to grow 123% by 2031.
- Marpai leverages a national footprint to serve multi-state employers, a capability that regional competitors struggle with.
- Despite top-line struggles, the company emphasizes stabilization, renewed operational focus, and a pivot toward aggressive, sustainable growth phases.
- Employee lives data remain undisclosed, citing competitive reasons, but sales momentum indicates expanding client base.
- Marpai positions itself as a disruptor in the $5.5 trillion U.S. healthcare market, aiming to improve efficiency and reach healthier patient outcomes.
Full Transcript
Conference Operator: Morning and welcome to Marpai Q3 2025 earnings webcast. All participants will be in listen-only mode. Should you need assistance, please signal the conference specialist by pressing star followed by zero. After today’s presentation, there will be an opportunity to ask questions. Please note that this conference is being recorded. I would now like to turn the conference over to Steve Johnson, Chief Financial Officer. Please go ahead.
Steve Johnson, Chief Financial Officer, Marpai: Thank you. Good morning, and thank you for joining us for the Marpai Q3 2025 earnings release webcast. With me this morning is Damien Lamendola, Director and CEO of Marpai, and Dallas Script, President and Chief Operating Officer of Marpai. Before we begin, I’d like to draw your attention to the forward-looking statements included in this presentation. Damien, the floor is yours.
Damien Lamendola, CEO and Director, Marpai: Thank you, Steve. Employers have two basic options when considering the health benefits for their employees. Fully funded with a traditional insurance company or self-funded, where the employer takes on the funding responsibilities for the health insurance benefits. Given the continued high rate of healthcare inflation, many more companies are choosing to self-fund their benefit programs and use a third-party administrator as generally, just by moving to a self-funded plan, it reduces overall costs by 10% or more. As more and more employers are quickly moving over to self-funded plans, the demand for TPA services has been increasing significantly. I’ll turn it over to Dallas now, who as Steve said is our President and Chief Operating Officer.
Dallas Script, President and Chief Operating Officer, Marpai: Thank you, Damien. Marpai has a national footprint, allowing us to serve employers with multi-state locations with ease, which many of our regional competitors really struggle to do. Marpai also offers significant cost savings programs, and our relaunch of Marpai Rx will be a game changer for us. As a leading independent TPA, we put our clients first. With a robust arsenal of services, Marpai assists with benefit plan design and aggressively negotiates on behalf of our clients to help manage their ever-rising costs. The TPA industry has a massive total addressable market of over $150 billion, and it’s poised to grow 123% by 2031, according to the recent research published by the Insight Partners. The primary reasons for the growth are rising healthcare costs, growing employer-sponsored health plans, technology advances, and further expansion of TPA offerings. I’ll now hand it over to Steve to cover the Q3 results.
Steve Johnson, Chief Financial Officer, Marpai: Thank you, Dallas. Net revenues were $4 million for the three months ended September 30, 2025, which was $3 million, or approximately 42% lower than Q3 last year. Our operating expenses were $3.9 million, or $1.2 million, or a 24% improvement over last year, Q3. Operating loss was $3.5 million in Q3 of 2025, $0.1 million, or a 2% improvement over Q3 last year. Our net loss was $3.0 million for the quarter, or $0.1 million, a 2% improvement over Q3 in 2024. Our basic and diluted loss per share was $0.20 for the three months ended September 30, 2025, an improvement of $0.10 per share from Q3 last year. We continue on our year-to-year progress, and one of the things we wanted to highlight was our cash and capital planning.
Our disciplined focus on efficiency has allowed us to substantially reduce the company’s cash burn, leaving us with $450,000 in unrestricted cash on hand at the end of Q3. As we recently announced, we completed a $3.9 million private investment in public equity, or PIPE, transaction. This successful capital raise, we believe, delivers the financial strength needed to fully fund the final stages of our high-growth turnaround plan. We strategically partnered with long-term-focused family office investors and committed insiders, a clear vote of confidence in Marpai’s future potential. Looking ahead, we are driving new efficiencies by consolidating our claims processing into a single, cutting-edge operating system. This key infrastructure upgrade is expected to unlock significant additional cost savings in our technology and infrastructure expense, further accelerating our path to profitability and fueling our next phase of growth.
I will now hand it over to Dallas to discuss operations and sales developments.
Dallas Script, President and Chief Operating Officer, Marpai: Thank you, Steve. First of all, I want to say that I’m very excited to be part of the Marpai team. I joined back at the start of Q3, and we can continue to make improvements and progress on a daily basis. We’ve shifted our operational emphasis towards retention and new business with clarity, alignment, and focus. It’s a client-centric approach that’s led by metrics and KPIs. We believe in the continuous improvement mindset, adjusting processes, and increasing self-service for 24/7 coverage and speed. As part of this initiative, I am pleased to report that the company will complete its rollout of the Empara Client Experience Tool in Q4. As you may be aware, 80% of new business for health benefit plans follow the calendar year, so we are right in the midst of our busiest 2026 sales cycle.
Currently, we have high double-digit new client deals already booked for January 1. This represents a substantial increase in our base business, and we believe there’s much more to come before the end of the year. As an aside, the company does not report employee lives data for competitive reasons. One key highlight I can share is that our Marpai Rx program has been a differentiating factor in our ability to win new business, and I have previously led two other TPAs, and Marpai Rx is a game changer for us. Now I’ll turn it back over to Damien to share some final thoughts.
Damien Lamendola, CEO and Director, Marpai: Thanks, Dallas. As Marpai’s CEO, Director, and largest shareholder, I continue to invest in Marpai, including $1.7 million in Q3, because I believe strongly in what we are building: smarter healthcare with better patient outcomes at significantly lower cost and a rapidly scalable platform that’s disrupting a $5.5 trillion a year U.S. healthcare market. My personal commitment, both financial and operational, reflects my deep, growing confidence in our experienced leadership team, our rapidly improving technology, and our ability to quickly execute on a hyper-growth strategy that leads to an unmatched sustainable profitability. Our mission is not to develop a cheaper healthcare program. It is to show a more efficient U.S. healthcare system with healthier patients, allowing us to care for more Americans. Previously, I founded a billion-dollar healthcare business 10 years ago. Marpai has already shown much, much greater significant potential. I am very proud of our team and organization.
We’ve asked a lot from our employees, and they have delivered. We haven’t forgotten that our members matter. As Dallas just outlined, through disciplined focus, we have stabilized our operations, fortified our financial foundation, and effectively earned us the right to look forward. The entire organization is now aligned and energized, having successfully navigated complexity, and we are strategically positioned to pivot from recovery to an aggressive, sustainable growth phase. Our focus is squarely on leveraging our renewed efficiencies to capture market share and deliver exceptional long-term value. At this time, I’ll turn it back to the operator to open the line for questions.
Conference Operator: Yes, sir. Thank you. We will now begin the question and answer session. To ask a question, you may press star, then one on your touchstone phone. If you’re using a speakerphone, please pick up the handset before pressing the keys. To withdraw your question, please press star, then two. At this time, we will pause momentarily to assemble our roster. Again, if you wish to ask a question, please press star, then number one.
Seems like there are no questions that came through. I will now turn the call over back to Steve Johnson. Oh, sorry. Yeah, I’ll turn the call over back to Steve Johnson for any closing remarks. Please go ahead, sir.
Steve Johnson, Chief Financial Officer, Marpai: Thank you. Again, thanks for joining us. For those of you who may have questions that were not able to get through or are on the line, please feel free to reach out to our investor relations website or to email me with the contact information available there for you. It is steve.johnson@marpaihealth.com. Again, thank you for your support, and look forward to the next earnings call after the end of the year. Bye-bye.
Conference Operator: Thank you. The conference call has now concluded. Thank you for attending today’s presentation. You may now disconnect.
